1

2024-02-13

1	Difference in TMPRSS2 usage by Delta and Omicron variants of SARS-CoV-2:
2	Implication for a sudden increase among children
3	
4	Sosuke Kakee ^{1, 2} , Kyosuke Kanai ¹ , Akeno Tsuneki-Tokunaga ¹ , Keisuke Okuno ² , Noriyuki
5	Namba², Katsuyuki Tomita³, Hiroki Chikumi4, Seiji Kageyama ^{1,*}
6	
7	¹ Division of Virology, Department of Microbiology and Immunology, Faculty of Medicine,
8	Tottori University, 86 Nishi-cho, Yonago, 683-8503 Japan
9	² Division of Pediatrics and Perinatology, Department of Multidisciplinary Internal Medicine,
10	Faculty of Medicine, Tottori University, 86 Nishi-cho, Yonago, 683-8503 Japan
11	³ Department of Respiratory Medicine, National Hospital Organization Yonago Medical
12	Center, Yonago 683-8518, Japan
13	⁴ Department of Infectious Diseases, 86 Nishi-cho, Yonago, 683-8503 Japan
14	
15	*Correspondence to Seiji Kageyama, MD PhD
16	Division of Virology, Department of Microbiology and Immunology, Faculty of Medicine,
17	Tottori University, 86 Nishi-cho, Yonago, 683-8503 Japan
18	Tel. +81-859-38-6081
19	E-mail skageyama@tottori-u.ac.jp
20	
21	ORCID Nos.
22	Kyosuke Kanai 0000-0002-7984-207X
23	Keisuke Okuno 0000-0003-1602-0527
24	Noriyuki Namba 0000-0002-3803-4500
25	Katsuyuki Tomita 0000-0002-4050-775X
26	Hiroki Chikumi 0000-0001-7325-4990
27	Seiji Kageyama 0000-0002-5220-6137
28	
29	Key words (MeSH): COVID-19, SARS-CoV-2, COVID-19 Virus variants, SARS-CoV-2 delta
30	variant, SARS-CoV-2 omicron variant
31	

2

2024-02-13

33 Abstract

34 It has been postulated from a combination of evidence that a sudden increase in COVID-19 cases 35 among pediatric patients after onset of the Omicron wave was attributed to a reduced requirement 36 for TMPRSS2-mediated entry in pediatric airways with lower expression levels of TMPRSS2. 37 Epidemic strains were isolated from the indigenous population in an area, and the levels of 38 TMPRSS2 required for Delta and Omicron variants were assessed. As a result, Delta variants 39 proliferated fully in cultures of TMPRSS2-positive Vero cells but not in TMPRSS2-negative Vero 40 cell culture (350-fold, Delta vs 9.6-fold, Omicron). There was no obvious age-dependent selection 41 of Omicron strains affected by the TMPRSS2 (9.6-fold, Adults vs. 12-fold, Children). A 42 phylogenetic tree was generated and Blast searches (up to 100 references) for the spread of strains 43 in the study area showed that each strain had almost identical homology (>99.5%) with foreign 44 isolates, although indigenous strains had obvious differences from each other. This suggested that 45 the differences had been present abroad for a long period. Therefore, the lower requirement for 46 TMPRSS2 by Omicron strains might be applicable to epidemic strains globally. In conclusion, the 47 property of TMPRSS2-independent cleavage makes Omicron proliferate with ease and allows 48 epidemics among children with fewer TMPRSS2 on epithelial surfaces of the respiratory organs. 49

3

2024-02-13

50 Introduction

51 Since COVID-19 was recognized at the end of the year 2019 [1], it spread globally within 52 several months and became a pandemic [2]. Although the pandemic continued with the 53 periodic emergence of new variants, it has become endemic in 2023. Indeed, the World Health 54 Organization (WHO) has reported that SARS-CoV-2 infections decreased in five of the six 55 WHO regions (-14% to -76%) except for the Western Pacific Region (+14%) (COVID-19 56 Epidemiological Update- 24 November 2023). Nevertheless, the WHO is still tracking several 57 lineages of Omicron variants and has identified four variants of interest: XBB.1.5, XBB.1.16, 58 EG.5 and BA.2.86. Fortunately, epidemic strains are no longer categorized as variants of 59 concern [3].

60 The Omicron wave caused a substantial increase in infections among children compared 61 with the Delta wave [4]. A study in UK reported that 117 pediatric patients were admitted 62 during the Delta wave (1 June 2021-21 December 2021) compared with 737 during the 63 Omicron wave (22 December 2021-30 September 2022), with the peak number of weekly 64 admissions being 14 for Delta and 53 for Omicron [5]. Another report from the UK 65 highlighted the increase in cases in children aged under 1 year old. The proportion of the 66 age group (<1 year) increased steeply to 42% of children admitted to hospital with COVID-67 19 in the 4-week period (14 December 2021 to 12 January 2022) in which Omicron variants 68 were becoming dominant in the UK according to Coronavirus (COVID-19) latest insights, 30 69 March 2023 (https://www.ons.gov.uk). The percentage in the Omicron wave was much higher 70 than those in earlier periods: 33% of children (8 months, January to August 2020), 30% (8 71 months, September 2020 to April 2021), and 30% (8 months, May 2021 to 13 December 2021). 72 Similarly, a US cohort also suggested that the incidence rate of SARS-CoV-2 infection with 73 the Omicron variant was 6 to 8 times that of the Delta variant in children younger than 5

4

2024-02-13

74 years [6].

75 There is a potential explanation for the substantial increase among children infected 76 with Omicron variants. Variants prevalent up to the period of the Delta wave were known to 77 make efficient use of transmembrane protease, serine 2 (TMPRSS2) for cell entry. However, 78 amino acid mutations in the spike protein of Omicron variants reduced the efficiency of the 79 TMPRSS2-mediated cell entry and favored the endocytosis pathway, which is a cell entry 80 pathway that does not use TMPRSS2 [7, 8]. It is also known that TMPRSS2 expression in 81 pediatric airway cells is lower than in adults. Therefore, it can be hypothesized that the 82 decreased availability of TMPRSS2 in the Omicron strain led to an increase in the number 83 of pediatric patients [9].

Several host-genetic factors of a gene cluster on chromosome 3 were reported to be involved in the proliferation of SARS-CoV-2 in the human body [10]. The risk-associated DNA segment modulated the expression of several chemokine receptors including CCR5 of SARS-CoV-2 carriers [11]. Other factors, such as inborn errors of type I interferons may also be involved in SARS-CoV-2 proliferation [12]. These findings suggest that it is favorable to carry out the characterization of epidemic SARS-CoV-2 strains spreading among an indigenous population to minimize the virus selection caused by such genetic factors.

91 In the present study, we isolated Delta and Omicron variants from patients who visited 92 two hospitals within a single city of Japan and assessed the required levels of TMPRSS2 for 93 the proliferation of these Delta and Omicron isolates to examine the cause of the sudden 94 increase in COVID-19 cases among pediatric patients immediately after the onset of the 95 Omicron wave.

5

2024-02-13

96 Materials and Methods

97 Ethical approval.

98 The present study was approved by the Institutional Review Board of the Faculty of 99 Medicine, Tottori University, Japan (No.20A138, October 30, 2020) and have conducted from 100 November 1, 2020, onwards. All procedures performed in studies involving human 101 participants were in accordance with the 1964 Helsinki declaration and its later amendments 102 or comparable ethical standards.

103

104 Ethical issues including informed consent.

105 Sample collection was carried out after obtaining informed consent from patients through 106 a website notification and/or poster presentations at the out-patient departments in two hospitals 107 ('opt-out' system). It was guaranteed that the freedom to decline participation as a research subject, 108 and refusal to participate would have no negative effect on the person, and that he/she would be 109 able to continue to receive necessary medical cares. Transparency was preserved to the patients 110 for all information and the information was ready to be discarded according to the patient will. 111 Medical records have been accessed only by selected persons on limited occasions. A guardian was 112 selected to protect human rights for a pediatric patient. Only when all the necessary conditions 113 were fulfilled as described above, patient samples were collected and shipped to the laboratory 114 anonymously.

115

116 Patient samples and virus isolation.

117 Nasopharyngeal swab or saliva samples were collected from SARS-CoV-2 PCR-positive
118 patients who visited Tottori University Hospital or Yonago Medical Center in Yonago city,
119 Tottori prefecture, Japan during the period from July 2021 to August 2022.

6

2024-02-13

120	The samples in 1 mL UTM media (Cat. 350C, Copan Japan, Kobe city, Japan) were
121	transported to our laboratory and a portion (300 $\mu L)$ was inoculated into a TMPRSS2-
122	expressing Vero cell line (VeroE6/TMPRSS2 [13], JCRB1819, JCRB Cell Bank, Suita city,
123	Osaka) and incubated at 37°C in a 5% CO2/ 95% air atmosphere for one hour. After removing
124	the residual inoculum by washing the surface of the cells extensively, the cells were
125	maintained in Dulbecco's Modified Eagle Medium supplemented with 5% fetal bovine serum
126	and antibiotics until cytopathic effect was observed. The supernatant was stored at -80°C as
127	viral stock until further analyses.

128

129 Infection in TMPRSS2-positive and TMPRSS2-negative cells.

130 One day before infection, two different Vero cell lines, TMPRSS2-positive and -negative 131 Vero cells (VeroE6 cell line lacking TMPRSS2 expression: Vero76 [14], IFO50410, JCRB Cell 132 Bank), were seeded onto a 6-well plate (1.0×10⁶ cells/well). Clinical isolates were inoculated 133 (1.0×10⁵copies) onto the cells and incubated at 37 °C for 1 hour. The cells were washed twice 134 with phosphate-buffered saline to remove inoculated viruses in culture supernatant and 135 maintained in culture medium (2 mL per well) for 72 hours. A portion of the culture 136 supernatant (140 µl) was collected at the indicated time points during the 72 hours culture 137 period and subjected to real-time reverse transcription-polymerase chain reaction (RT-PCR) 138 to determine the viral production levels using RNA copy number in the culture medium.

139

140 RNA extraction, reverse Transcription, and polymerase chain reaction.

Viral RNA was extracted using QIAamp Viral RNA Mini Kit (Qiagen, Tokyo, Japan) or
 ISOSPIN Viral RNA (NIPPON GENE, Tokyo, Japan). RT-PCR and the determination of
 cDNA sequences were performed using previously reported methods with slight

7

2024-02-13

144	modifications [15]. In brief, the coding regions of SARS-CoV-2 spike protein were amplified
145	by RT-PCR using a One Taq One-Step RT-PCR kit (New England BioLabs, Tokyo, Japan)
146	and a primer pair (35F: 5'-AAGGGGTACTGCTGTTATGT-3', 41R: 5'-
147	AGCTGGTAATAGTCTGAAGTG-3') for first round PCR. The first-round PCR products were
148	subjected to a second round PCR with Amplitaq Gold TM 360 Master Mix (Thermo Fisher
149	Scientific, Tokyo, Japan), and M13-tailed primer pairs 35F/35R(5'-
150	TTAATAGGCGTGTGCTTAGA-3'), 36F(5'-TCAGCCTTTTCTTATGGACC-3'/36R(5'-
151	TCCAAGCTATAACGCAGC-3'), 37F(5'-TTAGAGGTGATGAAGTCAGA-3')/37R(5'-
152	TGTTCAGCCCCTATTAAACA-3'), 38F(5'-TAACCAGGTTGCTGTTCTTT-3')/38R(5'-
153	CAATCATTTCATCTGTGAGCA-3'), 39F(5'-CAGATCCATCAAAACCAAGC-3'/39R(5'-
154	GCAAGAAGACTACACCATGA-3'), 40F(5'-TCAGAGCTTCTGCTAATCTTG-3')/40R(5'-
155	GTAATTTGACTCCTTTGAGC-3'), and 41F(5'-TTGCCATAGTAATGGTGACA-
156	3')/41R(AGCTGGTAATAGTCTGAAGTG-3'). For Omicron BA5 variants, a modified primer
157	37FBA5(5'-TTAGAGGTAATGAAGTCAGC-3') was used instead of the 37F primer in the
158	second round PCR. The second round PCR products were then subjected to the sequencing
159	reactions.

160

161 Determination of nucleotide sequences.

162 Nucleotide sequences were determined using a BigDye Terminators v3.1 Cycle Sequence 163 kit in accordance with the manufacturer's instructions (Thermo Fisher Scientific). Isolated 164 viruses were subtyped using the sequencing results. Variants were classified into two groups 165 according to age (Adults: 16 years or older and Children: 15 years or younger). The key amino 166 acids of spike protein were analyzed in the relation to usage of TMPRSS2 and endocytosis.

8

2024-02-13

168 Phylogenetic analysis.

169 The nucleotide sequences of the amplified spike region were determined using a BigDye. 170Terminator v3.1 Cycle Sequencing kit in accordance with the manufacturer's instructions 171 (Life Technologies). M13 and PCR primers were used for the sequencing reaction. Nucleotide 172sequences excluding the primer regions (3,822 bases encoding the spike region, 21,563-25,384 173 of Wuhan-Hu-1) were aligned with sequences obtained from the International Nucleotide 174Sequence Database. Of 69 sequences, 20 spike sequences were determined partially, but 175 these encompassed the region (22,824-24,152 of Wuhan-Hu-1). Inspection, manual 176 modification, and evolutionary analysis of the sequences were conducted in Molecular 177Evolutionary Genetics Analysis Version X (MEGA X). A phylogenetic tree was constructed 178 using the neighbor-joining method (1,000 bootstrap replications) in MEGA X. An estimate of 179 the mean evolutionary diversity was also conducted using MEGA X [16]. The lineage of 180 SARS-CoV-2 Omicron variant was determined using the International Nucleotide Sequence 181 Databases (https://www.insdc.org).

182

183 Statistical analysis.

184 Statistical analyses were performed using the Mann-Whitney U test and a P-value less

185 than 0.05 was considered statistically significant.

9

2024-02-13

187 **Results**

188 Properties of viral isolates

189 Delta variants were isolated from nine adults, but none were obtained from pediatric 190 patients because of extreme rarity of infections in this population. Omicron variants were 191 isolated from 38 adults and 22 from pediatric patients (Table 1). Delta variants were collected 192 from July to September 2021. Omicron variants were collected from adults from January to 193 July 2022, whereas those from pediatric patients were obtained in almost simultaneous 194 period from January to August 2022. Among the key amino acids in the spike protein of 195 SARS-CoV-2 related to the efficiency of S1/S2 and S2' cleavage, P681R was detected in all 196 analyzed Delta variants. As for the Omicron variants, H655Y, N679K, and P681H were 197 detected in all strains analyzed in the present study (Table 1).

Nucleotide sequences of SARS-CoV-2 spike genes of the tested samples (GenBank
 accession numbers, LC793397-LC793465) were mostly identical to the reference strains
 retrieved from the International Nucleotide Sequence Database using Betacoronavirus
 BLAST (>99.63% similarity with 100 references) (Figure 1).

202

Different proliferation efficiency of Delta and Omicron variants in TMPRSS2-positive and negative cells

The amount of progeny viruses of Delta variants in supernatants was significantly higher in cultures of Vero cells in the presence of TMPRSS2 at all sampling times at 24, 48 and 72 hours post infection (Figure 2A). Viral proliferation level is obviously higher in cultures of Vero cells with TMPRSS2. However, the level became more similar in the absence of TMPRSS2 (Figure 2B). As assessed at 24 hours post-infection, Delta variants were produced at significantly higher levels by Vero cells in the presence of TMPRSS2 (350x)

10

211	compared with its absence (Figure 2C, left). Contrary to the production of Delta variants,
212	Omicron variants proliferated equally in TMPRSS2-postive and -negative cell cultures (9.6x)
213	(Figure 2C, right).
214	The production levels of Omicron variants from adults and children were equivalent in
215	the culture of Vero cells with and without TMPRSS2, although it was slightly superior in
216	cultures of the cells with TMPRSS2 (Figure 3).
217	

11

2024-02-13

218 Discussion

Nucleotide sequences of SARS-CoV-2 genes showed extremely high homology (more than 99.5%) with the reference strains. Although Delta variants were produced at significantly higher levels from Vero cells in the presence of TMPRSS2 *in vitro*, Omicron variants proliferated equally in TMPRSS2-postive and -negative cell cultures. Omicron variants from adults and children produced equivalent levels in the cultures of Vero cells regardless of the presence of TMPRSS2.

225 It has been reported that China has the lowest nucleotide diversity of SARS-CoV-2, 226followed by Europe and lastly by the USA and that the difference in such diversity coincides 227 with virus transmission time order: starting in China, then Europe and finally the USA [17]. 228 Although mutations have been accumulated over time, the diversity among circulating 229 strains seems very low, and SARS-CoV-2 consensus sequences were reported to be 230 indistinguishable, and they differed by 1 to 2 mutations in the rest in most of multi-infection 231 households [18]. Others reported that substitutions were concentrated in the spike protein, 232 at a rate of 0.21 amino acid residues per month [19]. Transmission efficiency depends on the 233 unique profile of intra-host viral clones [20-22]. These findings can be attributed to the 234inherent nature of SARS-CoV-2 originated from its unique function of 3'-to-5' exoribonuclease 235 leading to high replication fidelity [23, 24]. These mutational trends were equivalent to our 236 data shown in the phylogenetic tree from the present study. Mostly identical reference 237 strains (>99.5% homology) were found among 100 strains computed in a Betacoronavirus 238 BLAST search, suggesting the imported strains spread in the study area without any 239 mutation. The profile of key amino acids in the spike protein affecting S2' cleavage was 240 identical to the reported ones [25-27]. Therefore, the properties of the Delta and Omicron 241 variants reported elsewhere is presumably applicable to the strains in the present study.

12

2024-02-13

242	SARS-CoV-2 uses ACE2 for entry and the serine protease TMPRSS2 for spike protein
243	priming [28]. In the present study, the properties of TMPRSS2 were highlighted and the
244	degree of requirement for the TMPRSS2 molecule was assessed using clinical strains of Delta
245	and Omicron variants. As a result, Delta variants lost the effective replication capability in
246	the absence of TMPRSS2, but Omicron variants did not lose it. The Delta variant-specific
247	dependence on the TMPRSS2 function was prevalent for the epidemic strains, as estimated
248	in a model study [7]. TMPRSS2-dependent Delta variants have rarely infected children
249	because of the lower expression of TMPRSS2 in their airway [9]. However, Omicron variants
250	do not need enzymatic cleavage by TMPRSS2 for the replication. Independency of TMPRSS2
251	in Omicron variants is applicable to the strains from adults and children. Clinical isolates
252	derived from adult and children grew equally in Vero cells regardless of the presence of
253	TMPRSS2.
254	It has been proposed that Delta variants predominantly use TMPRSS2 for the cleavage

255at a S2' site of the SARS-CoV-2 spike protein as compared with Omicron variants, although 256 both Delta and Omicron variants required membrane fusion for the viral replication via the 257 fusion peptide revealed by TMPRSS2 and/or Cathepsin L-mediated cleavage [7, 8, 28]. As expected, the predominant usage of TMPRSS2 by Delta variants was confirmed in the 258 259 present study using clinical isolates from an indigenous population with similar genetic 260 backgrounds. TMPRSS2-independent cleavage allows Omicron variants to proliferate with 261 ease in children possessing lower levels of TMPRSS2 on epithelial surfaces of the respiratory 262 organs [9].

This study was carried out at one site only and handled a limited number of samples. Similar studies are required at other sites to confirm the trends described in the present study. We failed in the sampling of Delta variants from pediatric patients because of rare

13

266	infections caused by Delta variants in the study field. Therefore, the difference in the usage
267	of TMPRSS2 by Delta and Omicron variants could not be examined directly using samples
268	from pediatric patients.
269	
270	Conclusion
271	Analysis of epidemic strains from indigenous populations with similar genetic backgrounds
272	in one area showed that the Omicron variants were able to replicate independently in
273	pediatric patients with lower levels of TMPRSS2 on epithelial surface of the respiratory.
274	
275	Acknowledgments
276	The authors are grateful to the patients who agreed to participate in this study and to
277	Dr. Perdana WY for technical assistance.
278	
279	Funding
280	This work was supported in part by a Grant-in-Aid for Scientific Research on Infection
281	Control and Prevention by the International Platform for Dryland Research and Education,
282	Tottori University.
283	
284	Conflict of interest.
285	The authors report no declarations of interest.
286	
287	

14

2024-02-13

288Legends to Figures

- 289 Figure 1. Phylogenetic tree of SARS-CoV-2 clinical isolates.
- 290 The phylogenetic tree was generated from the SARS-CoV-2 spike protein coding region.
- 291 Isolates from adults (>20 years, \bullet) and children (<14 years, \circ) (GenBank accession numbers,
- 292 LC793397-LC793465) are shown with reference strains (\blacktriangle). The reference strains with the
- 293 greatest distances from the present isolates were selected from the result of BLAST searches
- 294 of 100 beta-coronavirus sequences in the International Nucleotide Sequence Databases. The
- 295 scale shown the genetic distance. Wuhan-Hu-1 (NC_045512) was used as the outgroup.
- 296

297 Figure 2. Proliferation efficiency of the Delta and Omicron variants from adult patients in 298 TMPRSS2-positive or -negative Vero cells.

299 (A) The production levels of Delta variants (n=3, GenBank accession numbers, LC793397-300 LC793399) were determined by SARS-CoV-2 genomic RNA copy number in culture 301 supernatants and compared between TMPRSS2-positive (•) and -negative (o) Vero cell 302 cultures up to 72 hours. Data plots are shown as mean±SD from three independent 303 experiments. (B) The levels of Omicron variants (n=3, LC793430-LC793432) were also 304 compared similarly. (C) Means and distributions of the production levels of Delta (n=6, LC793397-LC793400, LC793404, LC793405) and Omicron variants (n=24, LC793430-305 306 LC793442, LC793444-LC793452, LC793455, LC793456) in the supernatants of TMPRSS2-307 positive (P) or -negative (N) Vero cell culture at 24 hours post-infection are shown as box-308 and-whisker plots. The levels of P and N were compared among Delta/Adult and 309 Omicron/Adult isolates and showed significant difference (P<0.05, Mann-Whitney U test).

15

- Figure.3 Proliferation efficiency of Omicron variant clinical isolates from adult or pediatric
 patients in TMPRSS2-positive or -negative Vero cells.
- 313 (A) The production levels of Omicron variants from adults (n=3, GenBank accession numbers,
- 314 LC793430-LC793432) were determined similarly in TMPRSS2 positive (•) or negative (•)
- 315 Vero cell culture as shown in Figure 2. (B) The levels of Omicron variants from children (n=3,
- 316 LC793408-LC793410) were also assessed in the same manner. (C) Means and distributions
- 317 of the production of Omicron variants from adults (n=24, LC793430-LC793442, LC793444-
- 318 LC793452, LC793455, LC793456) and pediatric patients (n=21, LC793408-LC793415,
- 319 LC793417-LC793429) in the supernatants of TMPRSS2-positive (P) or negative (N) Vero cell
- 320 cultures at 24 hours post-infection are shown as box-and-whisker plots. No significant 321 difference was detected between the values of P and N in omicron/adults and
- 322 omicron/children (Mann-Whitney U test).
- 323
- 324

2024-02-13

16

325 References

326 Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients 1. 327 with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-33. Epub 2020/01/25. doi: 328 10.1056/NEJMoa2001017. PubMed PMID: 31978945; PubMed Central PMCID: 329 PMCPMC7092803.

330 Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of 2.331 COVID-19-related mortality, 2020-21. Lancet. 2022;399(10334):1513-36. Epub 2022/03/14. 332 doi: 10.1016/s0140-6736(21)02796-3. PubMed PMID: 35279232; PubMed Central PMCID: 333 PMCPMC8912932.

334 Telenti A, Hodcroft EB, Robertson DL. The Evolution and Biology of SARS-CoV-2 3. 335 Variants. Cold Spring Harb Perspect Med. 2022;12(5). Epub 2022/04/22. doi: 336 10.1101/cshperspect.a041390. PubMed PMID: 35444005; PubMed Central PMCID: 337 PMCPMC9159258.

338 4. Koelle K, Martin MA, Antia R, Lopman B, Dean NE. The changing epidemiology of 339 SARS-CoV-2. 2022;375(6585):1116-21. Science. Epub 2022/03/11. doi: 340 10.1126/science.abm4915. PubMed PMID: PubMed Central PMCID: 35271324; 341 PMCPMC9009722.

342 5. Cheng DR, Schrader S, McMinn A, Crawford NW, Tosif S, McNab S, et al. Paediatric 343 admissions with SARS-CoV-2 during the Delta and Omicron waves: an Australian single-344 centre retrospective study. BMJ Paediatr Open. 2023;7(1). Epub 2023/03/08. doi: 345 10.1136/bmjpo-2023-001874. PubMed PMID: 36882231; PubMed Central PMCID: 346 PMCPMC10008196.

347 Wang L, Berger NA, Kaelber DC, Davis PB, Volkow ND, Xu R. Incidence Rates and 6. 348 Clinical Outcomes of SARS-CoV-2 Infection With the Omicron and Delta Variants in 349 Children Younger Than 5 Years in the US. JAMA Pediatr. 2022;176(8):811-3. Epub 350 2022/04/02. doi: 10.1001/jamapediatrics.2022.0945. PubMed PMID: 35363246; PubMed 351 Central PMCID: PMCPMC8976262.

352 Meng B, Abdullahi A, Ferreira I, Goonawardane N, Saito A, Kimura I, et al. Altered 7. 353 TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature. 354 2022;603(7902):706-14. Epub 2022/02/02. doi: 10.1038/s41586-022-04474-x. PubMed PMID: 355 35104837; PubMed Central PMCID: PMCPMC8942856.

356 Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS-CoV-2 entry into cells. 8. 357 Nat Rev Mol Cell Biol. 2022;23(1):3-20. Epub 2021/10/07. doi: 10.1038/s41580-021-00418-x. 358 PubMed PMID: 34611326; PubMed Central PMCID: PMCPMC8491763.

359 Schuler BA, Habermann AC, Plosa EJ, Taylor CJ, Jetter C, Negretti NM, et al. Age-9. 360 determined expression of priming protease TMPRSS2 and localization of SARS-CoV-2 in lung

17

- 361 epithelium. J Clin Invest. 2021;131(1). Epub 2020/11/13. doi: 10.1172/jci140766. PubMed 362 PMID: 33180746; PubMed Central PMCID: PMCPMC7773394.
- 363 10. Zeberg H, Pääbo S. The major genetic risk factor for severe COVID-19 is inherited from 364 Neanderthals. Nature. 2020;587(7835):610-2. Epub 2020/10/01. doi: 10.1038/s41586-020-365 2818-3. PubMed PMID: 32998156.
- 366 11. Zeberg H. The major genetic risk factor for severe COVID-19 is associated with 367 protection against HIV. Proc Natl Acad Sci U S A. 2022;119(9). Epub 2022/02/24. doi: 368 10.1073/pnas.2116435119. PubMed PMID: 35193979; PubMed Central PMCID: 369 PMCPMC8892305.
- 370 12. Zhang Q, Bastard P, Cobat A, Casanova JL. Human genetic and immunological 371 determinants of critical COVID-19 pneumonia. Nature. 2022;603(7902):587-98. Epub 372 2022/01/29. doi: 10.1038/s41586-022-04447-0. PubMed PMID: 35090163; PubMed Central 373 PMCID: PMCPMC8957595.
- 374 13. Matsuyama S, Nao N, Shirato K, Kawase M, Saito S, Takayama I, et al. Enhanced 375 isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc Natl Acad Sci U S A. 376 2020;117(13):7001-3. Epub 2020/03/14. doi: 10.1073/pnas.2002589117. PubMed PMID: 377 32165541; PubMed Central PMCID: PMCPMC7132130.
- 378 14. Nao N, Sato K, Yamagishi J, Tahara M, Nakatsu Y, Seki F, et al. Consensus and 379 variations in cell line specificity among human metapneumovirus strains. PLoS One. 380 2019;14(4):e0215822. Epub 2019/04/24. doi: 10.1371/journal.pone.0215822. PubMed PMID: 381 31013314; PubMed Central PMCID: PMCPMC6478314.
- 382 15. Moniruzzaman M, Hossain MU, Islam MN, Rahman MH, Ahmed I, Rahman TA, et al. 383 Coding-Complete Genome Sequence of SARS-CoV-2 Isolate from Bangladesh by Sanger 384 Sequencing. Microbiol Resour Announc. 2020;9(28). Epub 2020/07/11. doi: 385 10.1128/mra.00626-20. PubMed PMID: 32646908; PubMed Central PMCID: 386 PMCPMC7348026.
- 387 16. Kumar S, Stecher G, Li M, Knyaz C, Tamura K. MEGA X: Molecular Evolutionary 388 Genetics Analysis across Computing Platforms. Mol Biol Evol. 2018;35(6):1547-9. Epub 389 2018/05/04. doi: 10.1093/molbev/msy096. PubMed PMID: 29722887; PubMed Central 390 PMCID: PMCPMC5967553.
- 391 17. Chen YH, Wang H. Exploring Diversity of COVID-19 Based on Substitution Distance. 392 Infect Drug Resist. 2020;13:3887-94. Epub 2020/11/06. doi: 10.2147/idr.S277620. PubMed 393 PMID: 33149633; PubMed Central PMCID: PMCPMC7605616.
- 394 18. Bendall EE, Paz-Bailey G, Santiago GA, Porucznik CA, Stanford JB, Stockwell MS, et 395
- al. SARS-CoV-2 Genomic Diversity in Households Highlights the Challenges of Sequence-
- 396 Based Transmission Inference. mSphere. 2022;7(6):e0040022. Epub 2022/11/16. doi:

18

- 397 10.1128/msphere.00400-22. PubMed PMID: 36377913; PubMed Central PMCID: 398 PMCPMC9769559.
- 399 19. Lou J, Zhao S, Cao L, Zheng H, Chen Z, Chan RWY, et al. Temporal Patterns in the 400 Evolutionary Genetic Distance of SARS-CoV-2 during the COVID-19 Pandemic. Public 401 Health Genomics. 2022:1-4. Epub 2022/01/06. doi: 10.1159/000520837. PubMed PMID: 402 34986485.
- 403 20. Braun KM, Moreno GK, Wagner C, Accola MA, Rehrauer WM, Baker DA, et al. Acute 404 SARS-CoV-2 infections harbor limited within-host diversity and transmit via tight 405 transmission bottlenecks. PLoS Pathog. 2021;17(8):e1009849. Epub 2021/08/24. doi: 406 10.1371/journal.ppat.1009849. PubMed PMID: 34424945; PubMed Central PMCID: 407 PMCPMC8412271.
- 408 21. Valesano AL, Rumfelt KE, Dimcheff DE, Blair CN, Fitzsimmons WJ, Petrie JG, et al. 409 Temporal dynamics of SARS-CoV-2 mutation accumulation within and across infected hosts.
- 410 PLoS Pathog. 2021;17(4):e1009499. Epub 2021/04/08. doi: 10.1371/journal.ppat.1009499.
- 411 PubMed PMID: 33826681; PubMed Central PMCID: PMCPMC8055005.
- 412 22. Tonkin-Hill G, Martincorena I, Amato R, Lawson ARJ, Gerstung M, Johnston I, et al. 413 Patterns of within-host genetic diversity in SARS-CoV-2. Elife. 2021;10. Epub 2021/08/14. 414 10.7554/eLife.66857. PubMed PMID: 34387545; PubMed Central PMCID: doi∶ 415 PMCPMC8363274.
- 416 23. Bouvet M, Lugari A, Posthuma CC, Zevenhoven JC, Bernard S, Betzi S, et al. 417 Coronavirus Nsp10, a critical co-factor for activation of multiple replicative enzymes. J Biol 418 Chem. 2014;289(37):25783-96. Epub 2014/07/31. doi: 10.1074/jbc.M114.577353. PubMed 419 PMID: 25074927; PubMed Central PMCID: PMCPMC4162180.
- 420 24. Liu C, Shi W, Becker ST, Schatz DG, Liu B, Yang Y. Structural basis of mismatch 421 recognition by a SARS-CoV-2 proofreading enzyme. Science. 2021;373(6559):1142-6. Epub 422 2021/07/29. doi: 10.1126/science.abi9310. PubMed PMID: 34315827; PubMed Central 423 PMCID: PMCPMC9836006.
- 424 25. Hu B, Chan JF, Liu H, Liu Y, Chai Y, Shi J, et al. Spike mutations contributing to the 425 altered entry preference of SARS-CoV-2 omicron BA.1 and BA.2. Emerg Microbes Infect.
- 426 2022;11(1):2275-87. Epub 2022/08/31. doi: 10.1080/22221751.2022.2117098. PubMed PMID:
- 427 36039901; PubMed Central PMCID: PMCPMC9542985.
- 428 26. Beaudoin CA, Pandurangan AP, Kim SY, Hamaia SW, Huang CL, Blundell TL, et al. In 429 silico analysis of mutations near S1/S2 cleavage site in SARS-CoV-2 spike protein reveals 430 increased propensity of glycosylation in Omicron strain. J Med Virol. 2022;94(9):4181-92. 431 Epub 2022/05/17. doi: 10.1002/jmv.27845. PubMed PMID: 35575289; PubMed Central 432 PMCID: PMCPMC9348480.

19

2024-02-13

433 27. Khatri R, Siddqui G, Sadhu S, Maithil V, Vishwakarma P, Lohiya B, et al. Intrinsic 434 D614G and P681R/H mutations in SARS-CoV-2 VoCs Alpha, Delta, Omicron and viruses 435 with D614G plus key signature mutations in spike protein alters fusogenicity and infectivity. 436 Med Microbiol Immunol. 2023;212(1):103-22. Epub 2022/12/31. doi: 10.1007/s00430-022-437 00760-7. PubMed PMID: 36583790; PubMed Central PMCID: PMCPMC9801140. 438 28. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. 439 SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically 2020;181(2):271-80.e8. 2020/03/07. 440Proven Protease Inhibitor. Cell. Epub doi: 441 10.1016/j.cell.2020.02.052. PubMed PMID: 32142651; PubMed Central PMCID:

442 PMCPMC7102627.

Figure 1



Figure 2



Figure 3

